ATE380345T1 - Cvd-assay - Google Patents

Cvd-assay

Info

Publication number
ATE380345T1
ATE380345T1 AT03786143T AT03786143T ATE380345T1 AT E380345 T1 ATE380345 T1 AT E380345T1 AT 03786143 T AT03786143 T AT 03786143T AT 03786143 T AT03786143 T AT 03786143T AT E380345 T1 ATE380345 T1 AT E380345T1
Authority
AT
Austria
Prior art keywords
calprotectin
antibody
assay
cvd
body fluid
Prior art date
Application number
AT03786143T
Other languages
English (en)
Inventor
Erling Sundrehagen
Original Assignee
Axis Shield Asa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axis Shield Asa filed Critical Axis Shield Asa
Application granted granted Critical
Publication of ATE380345T1 publication Critical patent/ATE380345T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4727—Calcium binding proteins, e.g. calmodulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Gyroscopes (AREA)
  • Optical Head (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Devices For Conveying Motion By Means Of Endless Flexible Members (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analyzing Materials By The Use Of Ultrasonic Waves (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT03786143T 2002-12-20 2003-12-22 Cvd-assay ATE380345T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0229747.1A GB0229747D0 (en) 2002-12-20 2002-12-20 Assay

Publications (1)

Publication Number Publication Date
ATE380345T1 true ATE380345T1 (de) 2007-12-15

Family

ID=9950111

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03786143T ATE380345T1 (de) 2002-12-20 2003-12-22 Cvd-assay
AT06021890T ATE427498T1 (de) 2002-12-20 2003-12-22 Verfahren fur herz-kreislauf-erkrankungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06021890T ATE427498T1 (de) 2002-12-20 2003-12-22 Verfahren fur herz-kreislauf-erkrankungen

Country Status (16)

Country Link
US (3) US10101325B2 (de)
EP (2) EP1573335B1 (de)
JP (2) JP4653492B2 (de)
CN (3) CN101893635B (de)
AT (2) ATE380345T1 (de)
AU (1) AU2003295142A1 (de)
CA (2) CA2729365C (de)
DE (2) DE60327007D1 (de)
DK (2) DK1573335T3 (de)
ES (2) ES2323475T3 (de)
GB (1) GB0229747D0 (de)
NO (1) NO20052161L (de)
PL (2) PL216385B1 (de)
PT (1) PT1573335E (de)
SI (1) SI1573335T1 (de)
WO (1) WO2004057341A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
US7659087B2 (en) 2004-07-23 2010-02-09 Aspenbio Pharma, Inc. Methods and devices for diagnosis of appendicitis
SG150497A1 (en) 2004-07-23 2009-03-30 Aspenbio Pharma Inc Methods and devices for diagnosis of appendicitis
EP1862805A1 (de) * 2006-06-01 2007-12-05 University of Zürich Verwendung von MRP 8/14-Konzentrationen zur Unterscheidung von Personen mit akutem Koronarsyndromrisiko
WO2010101950A1 (en) * 2009-03-02 2010-09-10 Catholic Healthcare West Diagnostic devices and methods of use
WO2010128033A2 (en) * 2009-05-07 2010-11-11 Novozymes A/S Method for purification of target polypeptides
US9574977B2 (en) * 2013-02-26 2017-02-21 Innova Prep Liquid to liquid biological particle concentrator with disposable fluid path
EP2511704A1 (de) 2011-04-13 2012-10-17 Immundiagnostik AG Testverfahren für intrinsisch akute Nierenverletzung
NO20110895A1 (no) * 2011-06-21 2012-12-24 Magne Fagerhol Kompetitive S100A9 immunoanalyser
ES2402457B2 (es) * 2011-10-19 2014-01-20 Universidade De Vigo Procedimiento para el diagnóstico de derrame pleural maligno mediante la determinación de la concentración de calprotectina en líquido pleural.
US9594999B2 (en) 2012-04-03 2017-03-14 X-Card Holdings, Llc Information carrying card comprising crosslinked polymer composition, and method of making the same
US9122968B2 (en) 2012-04-03 2015-09-01 X-Card Holdings, Llc Information carrying card comprising a cross-linked polymer composition, and method of making the same
AU2013315371A1 (en) * 2012-09-12 2015-04-09 Berg Llc Use of markers in the identification of cardiotoxic agents
EP2973236B1 (de) 2013-03-15 2019-01-09 X-Card Holdings, LLC Verfahren zur herstellung einer kernschicht für eine informationskarte und in diesem verfahren hergestellte produkte
ES2948232T3 (es) * 2017-02-07 2023-09-06 Lyfstone B V Biomarcadores para diagnosticar el riesgo de revisión del implante relacionado con el implante debido a un aflojamiento aséptico
EP3385712A1 (de) 2017-04-03 2018-10-10 Gentian AS Verbessertes calprotectin-assay
CN111094978B (zh) * 2017-05-09 2024-05-28 免疫诊断股份公司 免疫比浊法测定钙结合蛋白s100家族成员的方法
CN108196066A (zh) * 2018-01-22 2018-06-22 安徽伊普诺康生物技术股份有限公司 一种测定钙防卫蛋白的试剂盒及其制备使用方法
WO2019173455A1 (en) 2018-03-07 2019-09-12 X-Card Holdings, Llc Metal card
JP2023527702A (ja) * 2020-05-13 2023-06-30 ノルディック バイオサイエンス エー／エス カルプロテクチンアッセイ

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287202A (en) 1978-05-26 1981-09-01 Horrobin David F Treatment and/or prophylaxis of spasms of coronary arteries
JPS55162059A (en) * 1979-06-05 1980-12-17 Mochida Pharmaceut Co Ltd Measuring method for antigen, antibody or their complex and measurement reagent kit
US4401765A (en) * 1981-09-01 1983-08-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
US4480042A (en) * 1981-10-28 1984-10-30 E. I. Du Pont De Nemours And Company Covalently bonded high refractive index particle reagents and their use in light scattering immunoassays
GB8318754D0 (en) * 1983-07-11 1983-08-10 Fagerhol M K F Human proteins anti-sera test kits
JPS60139621A (ja) 1983-12-27 1985-07-24 Grelan Pharmaceut Co Ltd 抗血栓剤
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
EP0310361A3 (de) * 1987-09-30 1989-05-24 Beckman Instruments, Inc. Aus drei Verzahnungen bestehendes Konjugat und Verfahren zu seiner Verwendung
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
DE69027560T2 (de) * 1989-08-23 1997-01-09 Canon K.K., Tokio/Tokyo Methode zur Messung eines immunologisch aktiven Materials und Vorrichtung, die dazu geeignet ist
US5455160A (en) * 1993-05-27 1995-10-03 Fagerhol; Magne K. Diagnostic test and kit for disease or disorders in the digestive system
US5776348A (en) * 1995-02-07 1998-07-07 Massachusetts Institute Of Technology Mineral precipitation system and method for inhibiting mineral precipitate formation
PT937259E (pt) * 1996-11-01 2005-01-31 Magne K Fagerhol Processo para a extraccao de proteinas
ES2374621T3 (es) 1997-04-02 2012-02-20 The Brigham And Women's Hospital, Inc. Medios para evaluar el perfil de riesgo de un individuo de sufrir una enfermedad ateroesclerótica.
GB9816088D0 (en) * 1998-07-23 1998-09-23 Axis Biochemicals Asa System
WO2000011479A1 (en) * 1998-08-20 2000-03-02 Axis-Shield Asa Assay method for cardiovascular disease
ATE497171T1 (de) * 1999-07-05 2011-02-15 Leuven K U Res & Dev Von willebrand-faktor-aktivitätsnachweis
JP2003508453A (ja) 1999-08-31 2003-03-04 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アテローム性動脈硬化疾患の予防における診断的ツールとしての全身性炎症マーカー
FR2800636A1 (fr) * 1999-11-05 2001-05-11 Bio Merieux Particules composites, conjugues derives, leur procede de preparation et utilisations
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US20030059461A1 (en) * 2000-06-06 2003-03-27 Sibtech, Inc. Molecular delivery vehicle for delivery of selected compounds to targets
ATE438097T1 (de) * 2000-08-29 2009-08-15 Kyowa Medex Co Ltd Gut reproduzierbares agglutinations- immunoassayverfahren und reagenzien
JP2002318233A (ja) * 2001-04-19 2002-10-31 Shino Test Corp 測定対象物質の比濁法測定試薬及び測定対象物質の比濁法測定方法
JP3806694B2 (ja) * 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
GB0229747D0 (en) * 2002-12-20 2003-01-29 Axis Shield Asa Assay
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
US7623910B2 (en) * 2006-03-10 2009-11-24 University Of Rochester ECG-based differentiation of LQT1 and LQT2 mutation

Also Published As

Publication number Publication date
SI1573335T1 (sl) 2008-04-30
AU2003295142A1 (en) 2004-07-14
PT1573335E (pt) 2007-12-21
US20110318847A1 (en) 2011-12-29
CN102608326A (zh) 2012-07-25
WO2004057341A2 (en) 2004-07-08
CN1729398A (zh) 2006-02-01
JP2010019849A (ja) 2010-01-28
NO20052161D0 (no) 2005-05-03
EP1573335B1 (de) 2007-12-05
ES2323475T3 (es) 2009-07-16
EP1739430A2 (de) 2007-01-03
CA2729365A1 (en) 2004-07-08
DE60327007D1 (de) 2009-05-14
PL377476A1 (pl) 2006-02-06
CN101893635A (zh) 2010-11-24
EP1573335A2 (de) 2005-09-14
CN101893635B (zh) 2014-04-09
CN1729398B (zh) 2012-04-04
US20190049439A1 (en) 2019-02-14
NO20052161L (no) 2005-07-19
JP5744385B2 (ja) 2015-07-08
US20060134705A1 (en) 2006-06-22
US10101325B2 (en) 2018-10-16
EP1739430B1 (de) 2009-04-01
PL216385B1 (pl) 2014-03-31
CA2729365C (en) 2018-09-18
JP4653492B2 (ja) 2011-03-16
DE60317931D1 (en) 2008-01-17
ATE427498T1 (de) 2009-04-15
CA2504876A1 (en) 2004-07-08
DK1739430T3 (da) 2009-07-13
DK1573335T3 (da) 2008-04-14
JP2006510895A (ja) 2006-03-30
GB0229747D0 (en) 2003-01-29
ES2297250T3 (es) 2008-05-01
EP1739430A3 (de) 2007-01-17
PL394295A1 (pl) 2011-09-12
DE60317931T2 (de) 2008-11-13
WO2004057341A3 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
NO20052161D0 (no) Analysemetode for hjerte-karsykdom
Sener et al. Rapid real-time detection of procalcitonin using a microcontact imprinted surface plasmon resonance biosensor
WO2007011936A3 (en) Lateral flow assay and device using magnetic particles
WO2007061793A3 (en) Modified cardiolipin and uses therefor
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
NO20076656L (no) Forbedrede immunoassay metoder
DE602007012248D1 (de) Nanosensoren und entsprechende technologien
WO2009117510A3 (en) Multi-wavelength analyses of sol-particle specific binding assays
EP2538218A8 (de) Biochemische Marker zur Bewertung des CVD-Risikos
JP2012509477A5 (de)
DE602007010032D1 (de) Immunoassay mit mehreren analyten
WO2010038974A3 (ko) 이뮤노글로블린 에이 신증과 티지비엠 신증의 진단용 조성물 및 키트
DE602006021777D1 (de) Diagnoseverfahren für präeklampsie
MX2009003572A (es) Metodos para reducir interferencia optica en un dispositivo de fluido.
Salama et al. Chemiluminescent optical fiber immunosensor for detection of autoantibodies to ovarian and breast cancer-associated antigens
Singh et al. Elevated serum SIRT 2 may differentiate parkinson’s disease from atypical parkinsonian syndromes
DE60130919D1 (de) Durchflussvorrichtung, diagnostischer kit diese enthaltend und gebrauch für den nachweis von analyten in einer probe
SG157244A1 (en) Point of care test for the detection of exposure or immunity to dengue virus
ATE467128T1 (de) Kolloidale metallkonjugate
CN103575875A (zh) 一种新的功能化金纳米棒免疫探针及金纳米棒生物芯片的制备方法及应用
JP2009544971A5 (de)
WO2008067008A3 (en) A method for the quantitative evaluation of sex hormones in a serum sample
Liu et al. Capacitive immunosensing of polycyclic aromatic hydrocarbon and protein conjugates
DE60332479D1 (de) Holo-transcobalamin bindungspartner und ihre verwendung in cobalamintest
ATE520985T1 (de) Verfahren zur bestimmung von antigen und antikörper gegen das antigen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1573335

Country of ref document: EP